Poor
Not Aligned
Patient Risk:
Moderate
Summary
Multiple claims about exercise performance/conditioning outcomes and several urgency/action details are not supported by the provided label excerpts. The label evidence does not mention dark (cola-colored) urine, yet it is presented as an urgent-care trigger, which is not supported by the supplied prescribing information.
Category Scores
Accurate Statements
Rarely, Lipitor (atorvastatin) can cause serious muscle injury (myopathy/rhabdomyolysis).
Supported by provided label text describing rare cases of rhabdomyolysis with acute renal failure and discussion of myopathy/rhabdomyolysis risk (5.1, 6).
Serious muscle injury (myopathy/rhabdomyolysis) from Lipitor can become dangerous.
Supported by provided label text linking rhabdomyolysis with acute renal failure and recommending withholding/discontinuation with acute serious conditions suggestive of myopathy (5.1).
Muscle side effects from Lipitor are more likely with higher statin doses.
Consistent with label text indicating increased risk with higher doses of atorvastatin in the context of interacting conditions and strong CYP3A4 inhibitors (5.1, 7).
Muscle side effects from Lipitor are more likely with interactions with other medications.
Supported by label text stating risk of myopathy is increased with concurrent administration of specific interacting agents (7) and listing increased risk with strong CYP3A4 inhibitors and others (5.1).
Creatine kinase (CK) blood tests can be checked if muscle symptoms are present while on Lipitor.
Supported by label text that periodic CPK/CPK determinations may be considered in such situations and that myopathy involves elevations in CPK (5.1).
Interacting medicines may be reviewed if muscle symptoms are present while taking Lipitor.
Partially supported by label advice to discuss all medications with healthcare professional (17.1) and label discussion of interacting agents increasing risk (5.1, 7).
Unsupported Statements
Lipitor (atorvastatin) doesn’t usually reduce exercise progress directly.
No provided label text addresses exercise progress or direct effects on exercise performance.
Most people can exercise normally while taking Lipitor (atorvastatin).
No provided label text addresses ability to exercise normally or frequency of exercise-related functional impact.
Lipitor ... can have side effects that can make workouts feel harder, especially muscle-related symptoms.
Label supports reporting unexplained muscle pain/tenderness/weakness (5.1, 17.1) and that myopathy includes muscle aches/weakness (5.1), but does not support the claim that workouts feel harder.
Muscle aches or weakness (myalgias) from Lipitor can make it harder to lift weights, run, or recover between sessions.
Label describes muscle aches/weakness as features and reporting advice, but does not support specific exercise modalities or recovery-between-sessions claims.
There is no consistent evidence that Lipitor causes permanent muscle loss in most users.
No provided label text addresses permanent muscle loss or evidence consistency.
Exercise progress is usually affected only if side effects occur with Lipitor (atorvastatin).
No provided label text addresses exercise progress/conditioning outcomes.
For people who develop muscle symptoms from Lipitor, the limiting factor tends to be discomfort or true muscle injury rather than exercise being “blocked.”
Label does not discuss exercise being “blocked” or limiting factors in exercise.
Dark (cola-colored) urine is a reason to seek urgent medical care.
No provided label text mentions dark/cola-colored urine as a symptom.
A dose adjustment or switching to a different statin may be done for muscle symptoms while on Lipitor.
Provided label text emphasizes temporarily withholding or discontinuing if myopathy is diagnosed/suspected or CPK markedly elevated (5.1), but does not mention dose adjustment or switching to a different statin.
Contradictions
Important Omissions
Promptly reporting unexplained muscle pain, tenderness, or weakness (especially with malaise or fever) and discontinuation/withholding guidance when myopathy/marked CPK elevation is suspected/diagnosed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The inclusion of dark (cola-colored) urine as an urgent-care trigger is not supported by the provided label excerpts. Several other claims add or refine guidance around exercise outcomes and urgency thresholds that are not explicitly addressed in the provided prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Unsupported exercise-performance and urine-color urgency claims; missing label-supported symptom reporting and discontinuation/withholding instructions; some urgency language is more specific than provided label excerpts.
Suggested Improvement
Restrict statements to label-supported content in the provided sections: (1) myopathy/rhabdomyolysis risk described as muscle aches/weakness with CPK elevations and rare rhabdomyolysis with acute renal failure; (2) advise prompt reporting of unexplained muscle pain/tenderness/weakness (especially with malaise or fever) and temporary withholding/discontinuation when myopathy is diagnosed or suspected/CPK markedly elevated (5.1, 17.1); (3) discuss increased risk with specified interacting drugs and higher-risk contexts (5.1, 7). Remove dark (cola-colored) urine and exercise-progression/“blocked” framing unless supported by additional label text.